Johnson & Johnson and its subsidiaries will pay more than $2.2 billion – one of the largest health-care fraud settlements in history – to settle criminal and civil liabilities arising from marketing of Risperdal and its injectable version, Invega, for uses not approved by the FDA. J&J admitted to inappropriate promotion of Risperdal to treat elderly, non-schizophrenic patients for symptoms such as anxiety, agitation, depression, hostility and confusion. “The conduct at issue in this case jeopardized the health and safety of patients and damaged the public trust,” said Attorney General Eric Holder.
Of further interest:
Johnson & Johnson to Settle Risperdal Improper Marketing Case (NY Times)
Johnson & Johnson to pay $2.2B in U.S. health care fraud settlement (CBS News)
Johnson & Johnson $2.2B settlement over marketing Risperdal, Invega and Natrecor (Fox)
J&J fined $2.2 bn for faulty drug claims, kickbacks (Google)